MAPK
Las MAPK son una familia de quinasas de proteínas involucradas en una variedad de procesos celulares, incluyendo crecimiento, proliferación, diferenciación y respuestas al estrés. La vía de señalización MAPK consta de varios niveles, incluidos ERK, JNK y p38 MAPK, cada uno con roles distintos en la función celular. La desregulación de la señalización MAPK está vinculada al cáncer, las enfermedades inflamatorias y los trastornos metabólicos. En CymitQuimica, ofrecemos una amplia gama de inhibidores y activadores de MAPK para apoyar su investigación en biología celular, transducción de señales y mecanismos de enfermedades.
Se han encontrado 893 productos de "MAPK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
KRAS inhibitor-18
CAS:KRAS inhibitor-18 targets KRAS G12C; IC50: 4.74 μM. Inhibits p-ERK in cancer cells. Promising for pancreatic, colorectal, lung cancer research.Fórmula:C20H15ClF3N3O2SForma y color:SolidPeso molecular:453.87HPK1-IN-27
CAS:HPK1-IN-27 inhibits HPK1 (MAP4K1), a kinase with potential for cancer treatment, per patent WO2019016071A1, compound 38.Fórmula:C26H23F3N4O4Forma y color:SolidPeso molecular:512.48ZG1077
CAS:ZG1077, a covalent KRAS G12C inhibitor, is utilized in non-small cell lung cancer (NSCLC) research.Fórmula:C33H33F2N5O5SForma y color:SolidPeso molecular:649.71SOS1-IN-4
CAS:SOS1-IN-4 is a potent inhibitor of SOS1 (IC50: 56 nM) and can be used in the study of KRAS-C12C/SOS1 interactions.Fórmula:C24H29F2N4O2PForma y color:SolidPeso molecular:474.48KRAS G12C inhibitor 35
CAS:KRAS G12C inhibitor 35 targets KRAS G12C in cancer research (CN112920183A, compound 3).Fórmula:C31H27ClF2N6O3Forma y color:SolidPeso molecular:605.03KRAS G12C inhibitor 21
CAS:KRAS G12C inhibitor 21 is a KRAS G12C inhibitor.Fórmula:C34H30ClN3O4Forma y color:SolidPeso molecular:580.07TH-Z827
CAS:<p>TH-Z827 is a mutant-selective inhibitor targeting KRAS(G12D) with an IC50 of 2.4 μM, demonstrating specificity by not binding to KRAS(WT) or KRAS(G12C).</p>Fórmula:C30H38N6OPureza:98%Forma y color:SolidPeso molecular:498.66HPK1-IN-9
CAS:HPK1-IN-9: Potent MAP4K family kinase inhibitor targeting hematopoietic progenitor cells; potential in HPK1 diseases. (Patent WO2021213317A1)Fórmula:C30H33N7O2Forma y color:SolidPeso molecular:523.63Uplarafenib
CAS:Uplarafenib (B-Raf IN 10), a potent BRAF inhibitor (IC50: 50-100 nM), exhibits antitumor effects on solid cancers.Fórmula:C22H21F3N4O4SPureza:99.98%Forma y color:SolidPeso molecular:494.49DL-threo dihydrosphingosine
CAS:DL-threo dihydrosphingosine blocks ERK, inhibits smooth muscle proliferation, and works against growth factor/G-protein ERK activation.Fórmula:C18H39NO2Forma y color:SolidPeso molecular:301.51Inflachromene
CAS:Inflachromene (ICM) is an inhibitor of HMGB1 and HMGB expression with anti-inflammatory activity.Inflachromene is used in the study of epilepsy.Fórmula:C21H19N3O4Pureza:97.36% - 99.88%Forma y color:SolidPeso molecular:377.39MS934
CAS:<p>MS934, a novel VHL-recruiting MEK 1/2 degrader, exhibits potent anti-proliferative effects on HT-29 cell growth, achieving a GI50 of 0.023 μM.</p>Fórmula:C52H69F3IN7O6SPureza:98%Forma y color:SolidPeso molecular:1104.11KRAS G12C inhibitor 25
CAS:KRAS G12C inhibitor 25 blocks SOS1-mediated GDP/GTP swap in KRAS-G12C mutants; IC50: 0.48 nM (WO2021216770A1, comp. 3).Fórmula:C32H41N7O2Forma y color:SolidPeso molecular:555.71HPK1-IN-33
CAS:HPK1-IN-33 inhibits HPK1 with 1.7 nM potency, reduces IL-2 in Jurkat cells with 286 nM EC50, and is less effective in HPK1 KO cells.Fórmula:C18H16ClFN6Forma y color:SolidPeso molecular:370.81L 731734
CAS:L 731734 is a farnesyltransferase inhibitor.Fórmula:C19H38N4O3SForma y color:SolidPeso molecular:402.6KRAS G12C inhibitor 53
CAS:KRAS G12C inhibitor 53 (Compound 1) is a KRAS G12C inhibitor.Fórmula:C21H14ClF2N5O2Forma y color:SolidPeso molecular:441.82HPK1-IN-11
CAS:HPK1-IN-11 is a potent HPK1 inhibitor. HPK1-IN-11 has potential for the study of HPK1-related diseases.Fórmula:C27H25N5O2Forma y color:SolidPeso molecular:451.52KRAS G12C inhibitor 32
CAS:KRAS G12C Inhibitor 32, an eight-membered heterocyclic compound with nitrogen, acts as a potent inhibitor of KRAS G12C [1].Fórmula:C29H30Cl3FN6O3Pureza:98%Forma y color:SolidPeso molecular:635.94HPK1-IN-13
CAS:HPK1-IN-13 is a potent inhibitor of HPK1. HPK1-IN-12 has potential for the study of HPK1-related diseases.Fórmula:C25H24FN5O2Forma y color:SolidPeso molecular:445.49Glecirasib
CAS:Glecirasib (JAB-21822,KRAS G12C inhibitor 36) is an orally active KRAS G12C inhibitor that selectively binds to and inhibits KRAS G12C-dependent signalingFórmula:C31H26ClF4N7O2Pureza:99.7% - >99.99%Forma y color:SolidPeso molecular:640.03
